Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Market Closed 01-09 16:00:00 EST

3.94

+0.02

+0.51%

盘后4.00

+0.06+1.52%

19:59 EST

High4.05	Low3.86	Vol2.30M
Open4.00	D1 Closing3.92	Amplitude4.97%
Mkt Cap711.21M	Tradable Cap393.21M	Total Shares180.51M
T/O9.08M	T/O Rate2.31%	Tradable Shares99.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":3.94,"timestamp":1767992400000,"preClose":3.92,"halted":0,"volume":2301318,"hourTrading":{"tag":"盘后","latestPrice":4,"preClose":3.94,"latestTime":"19:59 EST","volume":49751,"amount":198374.6073,"timestamp":1768006789129},"delay":0,"floatShares":99798700,"shares":180510658,"eps":-1.438701,"marketStatus":"Market Closed","change":0.02,"latestTime":"01-09 16:00:00 EST","open":4,"high":4.05,"low":3.855,"amount":9082179.56308,"amplitude":0.049745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.438701,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1768208400000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":3.92,"preHourTrading":{"tag":"盘前","latestPrice":3.99,"preClose":3.92,"latestTime":"09:25 EST","volume":4741,"amount":18799.339855,"timestamp":1767968700019},"postHourTrading":{"tag":"盘后","latestPrice":4,"preClose":3.94,"latestTime":"19:59 EST","volume":49751,"amount":198374.6073,"timestamp":1768006789129},"volumeRatio":0.6684251088651807,"impliedVol":0.8082,"impliedVolPercentile":0.2151},"requestUrl":"/m/hq/s/PRME","defaultTab":"news","newsList":[{"id":"2593411405","title":"Prime Medicine Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2593411405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593411405?lang=en_us&edition=fundamental","pubTime":"2025-12-24 00:22","pubTimestamp":1766506920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 11:22 ET (16:22 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2593413520","title":"LifeSci Initiates Prime Medicine at Outperform With $6 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593413520?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:53","pubTimestamp":1766497988,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) has an average rating of overweight and mean price target of $6.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2589872040","title":"Prime Medicine Reports Positive Phase 1/2 Results for PM359 in Chronic Granulomatous Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2589872040","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589872040?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:05","pubTimestamp":1765112709,"startTime":"0","endTime":"0","summary":"Prime Medicine Inc. announced the publication of Phase 1/2 clinical data for PM359, its investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease , in the New England Journal of Medicine. The initial results from two patients in the trial showed rapid neutrophil and platelet engraftment, durable restoration of NADPH oxidase activity, and early clinical benefit without any safety concerns related to PM359. Both patients remained free of new CGD-related complications following treatment. The data will also be presented at the 67th American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine In","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL6jbdYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2210150020.SGD","BK4112","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014021.USD","IE00BGHQF748.EUR","BK4585","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","SG9999014013.SGD","BK4588","PRME","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2589720658","title":"Prime Medicine Announces the New England Journal of Medicine Publication of Pm359  Clinical Data for the Treatment of Chronic Granulomatous Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2589720658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589720658?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:05","pubTimestamp":1765112700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA2SCVQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"1101922585","title":"Stock Track | Prime Medicine (PRME) Plummets 5% Following Analyst's Cautious Hold Rating and Extended Development Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1101922585","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101922585?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:30","pubTimestamp":1763047823,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. (PRME) saw its stock price plummet by 5.04% during Thursday's intraday trading session, as investors reacted to a recent analyst report and concerns about the company's...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRME"],"gpt_icon":0},{"id":"1142813530","title":"Stock Track | Prime Medicine (PRME) Plunges 5% Following Analyst's Cautious Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1142813530","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142813530?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:30","pubTimestamp":1763047817,"startTime":"0","endTime":"0","summary":"Shares of Prime Medicine, Inc. (PRME) tumbled 5.04% in Thursday's intraday trading session, following a cautious Hold rating from H.C. Wainwright analyst Arthur He CFA. The biotech company, known for...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRME"],"gpt_icon":0},{"id":"2583612125","title":"Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2583612125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583612125?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:37","pubTimestamp":1763033836,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He CFA has reiterated their neutral stance on PRME stock, giving a Hold rating on November 11. Arthur He CFA has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-for-prime-medicine-inc-amid-promising-preclinical-results-and-extended-development-timeline-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-for-prime-medicine-inc-amid-promising-preclinical-results-and-extended-development-timeline-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"gpt_icon":0},{"id":"2582922023","title":"Prime Medicine Is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2582922023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582922023?lang=en_us&edition=fundamental","pubTime":"2025-11-12 04:43","pubTimestamp":1762893780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 15:43 ET (20:43 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"1100621035","title":"Stock Track | Prime Medicine Soars 5.25% as CEO Prepares to Speak at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1100621035","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100621035?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:02","pubTimestamp":1762873346,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. (PRME) saw its stock soar by 5.25% in Tuesday's pre-market trading, catching investors' attention ahead of a significant company event. The biotech firm's shares rallied as...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRME"],"gpt_icon":0},{"id":"2582512876","title":"Prime Medicine Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582512876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582512876?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:31","pubTimestamp":1762777860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 07:31 ET (12:31 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2581883191","title":"Prime Medicine files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2581883191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581883191?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:11","pubTimestamp":1762521062,"startTime":"0","endTime":"0","summary":"08:06 EST Prime Medicine (PRME) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2581880478","title":"Prime Medicine Inc: Files for Mixed Shelf Offering - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2581880478","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581880478?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:06","pubTimestamp":1762520783,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ0QJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2581020888","title":"Prime Medicine : Sales Agreement Prospectus Covers Offer, Sale of Shares of Common Stock of up to $200 Mln From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2581020888","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581020888?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:06","pubTimestamp":1762520783,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nFWN3WJ0QJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2581000714","title":"Prime Medicine Q3 EPS $(0.32) Misses $(0.26) Estimate, Sales $1.225M Beat $1.026M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2581000714","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581000714?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:46","pubTimestamp":1762519595,"startTime":"0","endTime":"0","summary":"Prime Medicine Q3 EPS $(0.32) Misses $(0.26) Estimate, Sales $1.225M Beat $1.026M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48716547/prime-medicine-q3-eps-0-32-misses-0-26-estimate-sales-1-225m-beat-1-026m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2581100771","title":"Prime Medicine Unveils Pipeline Progress and Clinical Milestones for Prime Editing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2581100771","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581100771?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:21","pubTimestamp":1762518092,"startTime":"0","endTime":"0","summary":"Prime Medicine Inc. provided an update on its progress in advancing Prime Editing technology for the treatment of genetic diseases. The company highlighted multiple clinical programs, including PM577 for Wilson's Disease, which is preparing for clinical entry in 2026, and PM647 for Alpha-1 Antitrypsin Deficiency, with initial clinical data expected in 2027. The pipeline also includes investigational programs for cystic fibrosis and chronic granulomatous disease. Prime Medicine emphasized the modularity of its platform, allowing for a broad range of genome editing capabilities, including the ability to correct, insert, or delete DNA sequences in any target tissue. The company is also seeking strategic partnerships to accelerate its pipeline and expand its reach. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDL6KwwmH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2581700794","title":"Prime Medicine Q3 net loss narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2581700794","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581700794?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:14","pubTimestamp":1762517687,"startTime":"0","endTime":"0","summary":"Prime Medicine Q3 net loss narrowsOverviewPrime Medicine Q3 net loss narrows to $50.6 mln from $52.5 mln last yearOperating expenses rise due to increased R&D costs, offset by lower G&A expensesCompan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL1N3WJ0GW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2581600226","title":"BRIEF-Prime Medicine, Inc. Q3 EPS USD -0.32","url":"https://stock-news.laohu8.com/highlight/detail?id=2581600226","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581600226?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516846,"startTime":"0","endTime":"0","summary":"BRIEF-Prime Medicine, Inc. Q3 EPS USD -0.32\n\n\nNov 07 (Reuters) - Prime Medicine, Inc. Q3 income from operations USD -53.973 million.\n\nQ3 operating expenses USD 55.198 million\nQ3 net income USD -50.582 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLX41FCA1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2581002251","title":"Prime Medicine Appoints Matthew Hawryluk as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2581002251","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581002251?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516817,"startTime":"0","endTime":"0","summary":"Prime Medicine Inc. has announced the appointment of Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer. Dr. Hawryluk will oversee business development, corporate strategy, and alliance management for the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine Inc. published the original content used to generate this news brief via GlobeNewswire  on November 07, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nNDLbqrDf2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","BK4139","BK4112","LU2210149790.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4588","LU0314104364.USD","BK4585","NDAQ","IE00BKPKM429.USD","PRME"],"gpt_icon":0},{"id":"2581002909","title":"Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2581002909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581002909?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nTUA1XXQMH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"2581900219","title":"Prime Medicine, Inc. Q3 Operating Expenses USD 55.198 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581900219","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581900219?lang=en_us&edition=fundamental","pubTime":"2025-11-07 20:00","pubTimestamp":1762516801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nPLX41FCA1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com","stockEarnings":[{"period":"1week","weight":0.1161},{"period":"1month","weight":-0.0901},{"period":"3month","weight":-0.3063},{"period":"6month","weight":-0.0943},{"period":"1year","weight":0.2508},{"period":"ytd","weight":0.1354}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.060692},{"month":2,"riseRate":0.333333,"avgChangeRate":0.064547},{"month":3,"riseRate":0,"avgChangeRate":-0.216854},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.102761},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.001492},{"month":6,"riseRate":0.666667,"avgChangeRate":0.318071},{"month":7,"riseRate":1,"avgChangeRate":0.211426},{"month":8,"riseRate":0,"avgChangeRate":-0.164067},{"month":9,"riseRate":0.333333,"avgChangeRate":0.111542},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141809},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}